|Bid||18.99 x 0|
|Ask||18.03 x 0|
|Day's range||18.60 - 19.56|
|52-week range||15.20 - 28.46|
|Beta (3Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||25.33|
Allschwil, Switzerland - April 18, 2019 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2019. Key figures US GAAP operating expenses in Q1 2019 at CHF 125 million ...
Idorsia Ltd (IDIA.SW) today issued the formal invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The invitation will be published in the Swiss Official Gazette of Commerce (Schweizerisches Handelsamtsblatt) and distributed to Shareholders by post on April 10, 2019, and is available, together with the Company`s Annual Report and Compensation Report, on www.idorsia.com/agm. In order to attend and vote at the Annual General Meeting, shareholders must be registered in the company`s shareholder register by April 24, 2019 at the latest.
Allschwil, Switzerland - February 7, 2019 Idorsia Ltd (SIX: IDIA) today announced its financial results for the full year 2018. Key Updates Advancing pipeline - four Phase 3 programs initiated Operational ...
Idorsia Ltd (IDIA.SW) today announced that the first patient has been included into REACT, a Phase 3 registration study to investigate the efficacy and safety of clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in patients following an aneurysmal subarachnoid hemorrhage.
Idorsia will publish its full year financial results 2018 on Thursday February 7, 2019, at 07:00 CET. An investor conference call and webcast will be held to discuss the results on the same day: Date: ...
Idorsia Ltd (IDIA.SW) today announced that the first patient has been enrolled into a multiple-dose study to evaluate the efficacy and safety of cenerimod, a selective S1P1 receptor modulator for the treatment of adults with systemic lupus erythematosus (SLE). Idorsia is investigating cenerimod, an oral once-daily tablet in patients with lupus. "Cenerimod was selected for development due to its unique properties in experimental models.
Idorsia Ltd (IDIA.SW) today announced that Phase 2 clinical studies with selatogrel (recommended INN for ACT-246475), Idorsia`s P2Y12 receptor antagonist, in patients with stable coronary artery disease (CAD) and patients with acute myocardial infarction (AMI) have met their pharmacodynamic objectives of significantly inhibiting platelet aggregation. The predefined extent of platelet aggregation inhibition was seen in at least 89% of the patients in both chronic and acute situations across doses. The company is now preparing for the end of Phase 2 meetings with Health Authorities where it will discuss the Phase 3 study.
Santhera Pharmaceuticals (SIX:SANN) and Idorsia Ltd (IDIA.SW) have entered into an agreement under which Santhera will acquire the option to exclusively in-license, by way of sub-license, the first-in-class dissociative steroid vamorolone in all indications and all countries worldwide except Japan and South Korea. Initial clinical data suggest that vamorolone has the anti-inflammatory efficacy of steroids with reduced steroid-associated safety concerns, which would represent a significant improvement over current standard of care glucocorticoid therapy in patients with Duchenne muscular dystrophy (DMD), vamorolone`s lead indication.
Idorsia Ltd (IDIA.SW) today announced that it has maintained the collaborative agreement with ReveraGen to research and co-develop vamorolone, a non-hormonal steroid modulator currently investigated for the treatment of Duchenne Muscular Dystrophy (DMD). In addition, the parties have agreed to a new structure of the agreement which makes milestone payments more dependent on commercial success. Under the renegotiated terms, Idorsia will be entitled to exercise an option to obtain the exclusive worldwide license rights on vamorolone at any time, but not later than upon receipt of the Phase 2b study results for a consideration of USD 20 million (previously USD 30 million).
Idorsia Ltd (IDIA.SW) today announced that a representative of former Axovan shareholders claims the demerger of Actelion and Idorsia would trigger the acceleration of all outstanding milestone payments for clazosentan and has filed a complaint with the arbitrator in Switzerland against Actelion. Since the responsibilities of the underlying share purchase agreement between Actelion and former Axovan shareholders have been transferred from Actelion to Idorsia, Idorsia is liable to pay the milestones referred to in the share purchase agreement. Idorsia Ltd is reaching out for more - We have more ideas, we see more opportunities and we want to help more patients.
Allschwil, Switzerland - 23 October 2018 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first nine months of 2018. Jean-Paul Clozel, MD and Chief Executive Officer, commented: ...
As Chief Commercial Officer Simon Jose will join the Idorsia Executive Committee Simon`s first priority will be to establish a commercial organization Allschwil, Switzerland - October 23, 2018 Idorsia ...
Allschwil, Switzerland - July 24, 2018 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2018. Jean-Paul Clozel, MD and Chief Executive Officer, commented: "We have ...
Date: Tuesday, July 24, 2018 Time: 14:00 CEST / 13:00 BST / 08:00 EDT The call will start with presentations by senior management, followed by a Q&A session (live access to the speakers). To support ...
NOT FOR RELEASE, PUBLICATION, DISTRIBUTION IN OR INTO THE UNITED STATES, ITALY, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATON OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAWS. Idorsia Ltd (SIX: IDIA, "Idorsia") today announced that it has successfully placed 11,912,000 new shares (the "Offer Shares"), corresponding to approximately 10% of Idorsia`s currently issued share capital, by way of an accelerated bookbuilding. Additionally, Idorsia successfully placed CHF 200 million of senior unsecured convertible bonds (the "Bonds") due 2024.
NOT FOR RELEASE, PUBLICATION, DISTRIBUTION IN OR INTO THE UNITED STATES, ITALY, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATON OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAWS. Idorsia Ltd (SIX: IDIA, "Idorsia") today announced the launch of concurrent offerings of a maximum of 11,912,000 new registered shares (the "Offer Shares") with a par value of CHF 0.05 per share and a maximum of CHF 200 million senior unsecured convertible bonds (the "Bonds") due 2024. The net proceeds from the concurrent offerings will allow Idorsia to fund the Phase 3 development of Idorsia`s promising late-stage pipeline comprising aprocitentan, clazosentan, lucerastat and nemorexant, as well as its diverse early-stage and preclinical pipeline.
Idorsia Ltd (IDIA.SW) today announced that the first patient has been enrolled into PRECISION, a Phase 3 study to investigate the efficacy and safety of aprocitentan for resistant hypertension management in adults. Hypertension, or high blood pressure, remains the most frequent addressable risk factor of cardiovascular morbidity/mortality outcomes, ahead of smoking and obesity, as reported by the 2015 Global Burden of Disease, Injuries, and Risk Factor Project collaborating with WHO. Patients whose blood pressure remains high despite receiving at least three antihypertensive medications from different classes, including a diuretic, at maximal tolerated dose are categorized as having resistant hypertension.
Idorsia Ltd (IDIA.SW) today announced that it is initiating a Phase 3 study, REACT, to investigate the efficacy and safety of clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in patients following an aneurysmal subarachnoid hemorrhage.